Articles tagged with Oncology
A team led by Carnegie Mellon researchers has developed an innovative at-home urine test to detect over 30 types of early-stage solid tumors. The technology, combining synthetic biology and nucleic acid nanotechnology, aims to provide a precise and convenient way to screen for cancer.
An AI model successfully automates lymph node segmentation and extranodal extension classification from pretreatment CT scans in HPV-associated oropharyngeal carcinoma. Predicted extranodal extension is independently associated with worse oncologic outcomes, highlighting the potential for improved treatment planning.
A new study discovers a previously unknown long noncoding RNA, EUDAL, that helps oral cancer cells survive chemotherapy by permanently activating the epidermal growth factor receptor. This RNA molecule blocks the cellular tagging system, allowing EGFR to remain active and promote autophagy in cancer cells.
Researchers at Sylvester Comprehensive Cancer Center are pioneering innovative approaches to treating complex movement disorders with advanced imaging and radiosurgery techniques. The new era of functional radiosurgery enables precise treatment without invasive procedures.
A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.
A recent study suggests that the rise in early-onset cancer incidence in the US population may not be as significant as initially thought. Much of the increase is attributed to increased diagnostic scrutiny and over-diagnosis, rather than a genuine rise in clinically meaningful cancer cases.
A new clinical trial report finds that stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer. The study included a larger patient population than previously published randomized studies and followed these patients for much longer.
A phase III trial suggests that post-operative radiation therapy can reduce cancer recurrence in patients with high-risk disease. Patients who received radiation experienced significantly fewer pelvic recurrences and improved locoregional recurrence-free survival compared to those who did not receive radiation.
A phase III trial comparing proton and photon radiation therapy for breast cancer found that patients report equally strong health-related quality of life with either treatment. Patients treated with protons were more likely to say they would recommend or choose it again, but overall patient-reported outcomes were similar.
A phase III trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. Excellent tumor control and fewer long-term side effects were seen with both treatments.
A large phase III trial found that stereotactic body radiation therapy (SBRT) preserves quality of life, with fewer declines in bowel and urinary functioning. However, SBRT does not outperform standard radiation therapy for disease-free survival, with higher rates of biochemical failure and rising PSA after treatment.
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
A new clinical trial found that adding a PSMA-targeting agent to stereotactic radiation therapy doubled progression-free survival in patients with limited metastatic prostate cancer. The study also showed that the treatment delayed hormone therapy by 24 months and improved local control.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center identify IGF2BP3 as a master switch linking cancer metabolism and RNA regulation in leukemia cells. The protein shifts energy breakdown and RNA modifications to support cell survival and multiplication.
A study has identified KIMA, a genomic signature associated with a poor treatment response in HR+/HER2- breast cancer patients. The signature, composed of nine genes, can predict disease progression and overall survival, enabling personalized therapy selection.
A new robot-assisted bronchoscope has been shown to diagnose tiny lung tumors in hard-to-reach areas with over 84% success rate, more than three times higher than traditional methods. The technology enables accurate diagnosis in patients where conventional bronchoscopy offers no viable option.
A new study suggests that low-dose aspirin can prevent cancer in older adults based on individual characteristics. The analysis found varying treatment effects among participants, highlighting the need for personalized approaches to cancer prevention.
A study by University of Florida researchers found that 93% of new cancer patients are exposed to at least one type of misinformation about cancer treatments. The most common sources were second-hand information from friends, family, social media, and news outlets. The study suggests that clinicians should assume their patients have be...
New research reveals that zebrafish models can help guide clinical decision-making in real-time for challenging pediatric cancer cases. The study shows that pre-clinical zebrafish models accurately predicted responses to 11 of 12 treatment regimens, providing robust and actionable treatment response data.
A large-scale randomized trial will examine whether AI supports radiologists in interpreting mammograms more accurately, reducing unnecessary callbacks and anxiety. The PRISM Trial, led by UCLA, aims to inform future policy decisions and best practices in breast cancer screening.
A new study from the University of California - Los Angeles Health Sciences suggests that regular mammograms may still offer significant benefits for women in their 80s. The study found that screened women were more likely to have surgery to remove the tumor and had a lower risk of cancer returning and dying compared to unscreened women.
A cohort study reveals oral bacteria and fungi as significant risk factors for pancreatic cancer development. The findings suggest that oral microbiota may serve as biomarkers to identify individuals at high risk of pancreatic cancer, potentially contributing to personalized prevention strategies.
Researchers at Graz University of Technology created a highly detailed digital twin of the A549 lung cancer cell line, paving the way for individualized cancer treatment. The model simulates calcium dynamics and electrical voltages, allowing for testing of drugs and personalized treatment strategies.
A large-scale population study found that oxaliplatin benefits only younger stage III patients, with no added survival benefit for those over 70. The study suggests using an age threshold to make evidence-based choices about chemotherapy.
A new study shows that remote perioperative monitoring significantly improves recovery for cancer surgery patients, with a 6% greater functional recovery rate by day 14 after surgery. The study also found fewer major complications and improved symptom management.
A cohort study suggests nicotinamide reduces skin cancer risk, with greatest effect seen after initial skin cancer diagnosis, indicating potential chemopreventive properties of the vitamin B3 derivative
A growing body of research links environmental pollutants to worsened health and shorter life spans in childhood cancer survivors. The study found that only 25% of pediatric oncology providers felt comfortable discussing environmental pollutant impacts with patients.
These rare tumors often present with aggressive behavior, early metastasis, and resistance to chemotherapy and radiotherapy. Early detection and disease staging are key factors associated with improved survival.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
A $1.7M Department of Defense grant funds the Convergent Science Virtual Cancer Center, strengthening expertise in cancer risks faced by military personnel and their families. The center provides personalized mentorship, immersive workshops, and non-traditional educational opportunities to improve patient outcomes across various cancers.
A new study highlights why kids' brain tumors need therapies designed for their unique biology, pointing to engineered immune cells and cancer vaccines as promising approaches. The review emphasizes the need for targeted treatments that recognize and fight childhood brain tumor differences.
Researchers found that lung cancer cells can form functional synapses with neurons, supporting their growth and survival. Disrupting glutamate signalling led to lower tumour burden and longer survival in experimental mice, highlighting promising therapeutic targets.
A consortium led by the University of Southampton aims to advance cutting-edge treatments for lung cancer, blood cancers, and chronic inflammation. The ON-TRACT project will train researchers in academic, industrial, and clinical settings to develop safer and more effective treatments.
A recent study published in the Lancet Primary Care tracked over 4,800 patients referred to the SCAN Pathway, a cancer diagnosis pathway designed for patients with non-specific symptoms. The study found that early diagnosis of cancers can save thousands of lives and reduce treatment costs for the NHS.
Researchers evaluated a tool based on NCCN Guidelines to identify high-risk medications and their association with frailty and outcomes in over 380,000 older adults diagnosed with cancer. The study found that each additional high-risk medication increased the odds of being mildly or moderately-to-severely frail by 66%.
Experts weighed in on the current state of artificial intelligence (AI) in cancer care, noting both its potential for improving efficiency and its challenges. Many expressed excitement over AI's possibilities for helping support an overburdened oncology workforce and accelerating the pursuit of new cures.
A clinical trial found that patients with mesothelioma who received combination immunotherapy drugs before surgery had successful surgeries and improved early outcomes. The study showed that tracking tumor DNA in the blood could help predict treatment benefit.
Researchers developed photo-inducible binary interaction tools (PhoBITs) to precisely control gene expression, cell signaling, and immune responses. PhoBITs enable targeted treatment with minimal side effects, opening new avenues for cancer therapy, immunotherapy, and regenerative medicine.
Phoenix SENOLYTIX and MD Anderson Cancer Center announced a cross-licensing agreement to further develop inducible switch technologies for use in cell and gene therapies. The partnership will enhance the development of these technologies, which can be used as safety features to regulate cell therapy activity.
The ASTRO's 2025 Annual Meeting will feature pivotal studies in radiation medicine, highlighting advances in radiopharmaceutical therapy and new indications for low-dose radiation therapy. The meeting will also explore cutting-edge techniques for prostate, breast, lung, and other common cancers.
Researchers discovered that disrupting protein quality control slows tumor growth in rhabdomyosarcoma, a rare and aggressive cancer primarily affecting children. The treatment, which targets the proteostasis network, significantly slowed or stopped tumor growth in mice implanted with human RMS tumors.
A study published in Oncoscience found that over 60% of oncology healthcare professionals in Morocco showed signs of severe burnout, with emotional exhaustion being the key factor. The study highlights the need for urgent institutional changes to support healthcare workers and improve work environments.
The Molecular Analysis for Precision Oncology Congress 2025 (MAP) brings together leading experts to explore the latest cancer research advances. Key topics include AI-integrated diagnostics and therapy, as well as immunotherapy and emerging developments in aging and cellular senescence.
Researchers evaluated clinical outcomes of endoscopic resection in sellar chondrosarcomas, revealing common symptoms like blurring of vision and headaches. The study also provides recommendations for accurate diagnosis using imaging data and clinical features.
A telephone-based weight loss intervention significantly reduced weight in breast cancer patients with overweight and obesity. The study suggests that this intervention may improve disease outcomes, warranting further investigation in future trials.
Researchers at the University of Navarra have developed FLIP-HEDOS, a model that simulates how much radiation blood absorbs during cancer treatment. The study highlights the importance of protecting blood from radiation, which can impair immune function and lead to hematologic toxicity.
Researchers envision AI-powered systems that identify patients at risk of mental health struggles, provide continuous psychological monitoring and tailor interventions. AI can also overcome barriers to mental health care by delivering support exactly where and when it's needed, including rural areas.
A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.
The International Osteoporosis Foundation has issued an updated joint position statement on managing aromatase inhibitor-associated bone loss in women with hormone-sensitive breast cancer. The guidelines incorporate recent clinical trials and systematic reviews to provide evidence-based treatment algorithms for assessing fracture risk ...
The FDA-approved MI Cancer Seek test is a comprehensive molecular profiling assay that delivers accurate and reliable results from minimal tissue input. It identifies key biomarkers linked to FDA-approved treatments for several major cancers, including breast, lung, colon, melanoma, and endometrial cancers.
A recent study reveals woefully low awareness of human papillomavirus (HPV), the HPV vaccine, and their association with cancer in the Midwestern and Southern US states. These states have seen a rise in HPV-associated cancers, making suboptimal HPV vaccination rates even more alarming.
A nationwide Swedish study found nearly three times as many young adults under 50 diagnosed with colorectal cancer today compared to the early 1990s. The disease has become two to three times more common in this age group, with underlying causes not fully understood.
A new study from the University of Missouri-Columbia highlights the importance of consistent primary care coordination in cancer survivorship care. The research found that only a third of patients consistently saw the same primary care clinician during and after cancer treatment, leading to fragmented care and gaps in patient services.
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients with high-risk non-muscle-invasive bladder cancer. The treatment was well-tolerated and showed improved outcomes compared to standard treatments.
A study published in The Lancet Gastroenterology & Hepatology found that routine AI assistance during colonoscopies can lead to a decrease in the ability of endoscopists to detect precancerous growths without AI aid. This reduction in skills may impact patient-related outcomes and highlight the need for further research on the long-ter...
The study found that only 16% of newly diagnosed patients with MDS on Medicare received HMAs during the period analyzed, with women and non-white patients being less likely to start treatment. The analysis suggests that making changes with existing therapies and administration can have a huge impact on improving outcomes in high-risk MDS.
Researchers have discovered a novel microbial consortium called AUN that produces exceptional tumor eradication in both murine and human cancer models. The therapy exhibits high biocompatibility and minimal side effects, offering a long-awaited solution for immunocompromised patients.
St. Jude receives its third consecutive Magnet designation and first Magnet Designation with Distinction, recognizing its commitment to exceptional nursing care and patient outcomes. The hospital's nursing programs, including the Nurse Residency Program and Center of Advanced Practice, have contributed to its success.
Local-stage colorectal cancer incidence among US adults ages 45-49 increased by 50% between 2021 and 2022, with a steep rise in 2019-2022. Screening rates also increased during this period, driven by recommendations to start screening at age 45.
Researchers found that decompression with a nasogastric tube is linked to reduced complications in patients after oesophageal cancer surgery. This challenges declining trend of abandoning the tube post-surgery, which was previously thought to be safe.